Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF

Standard treatments for nonsmall cell lung cancer (NSCLC), such as surgery, chemotherapy, and radiotherapy, often lead to disappointing results. Unfortunately, also the various immunotherapeutic approaches so far tested have not produced satisfactory results to be widely applied in the clinical prac...

Descripción completa

Detalles Bibliográficos
Autores principales: Corti, Angelo, Giovannini, Monica, Belli, Carmen, Villa, Eugenio
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2896845/
https://www.ncbi.nlm.nih.gov/pubmed/20613952
http://dx.doi.org/10.1155/2010/732680
_version_ 1782183395163373568
author Corti, Angelo
Giovannini, Monica
Belli, Carmen
Villa, Eugenio
author_facet Corti, Angelo
Giovannini, Monica
Belli, Carmen
Villa, Eugenio
author_sort Corti, Angelo
collection PubMed
description Standard treatments for nonsmall cell lung cancer (NSCLC), such as surgery, chemotherapy, and radiotherapy, often lead to disappointing results. Unfortunately, also the various immunotherapeutic approaches so far tested have not produced satisfactory results to be widely applied in the clinical practice. However, the recent development of new immunomodulatory agents may open promising therapeutic options. This paper focuses on PF3512676, lenalidomide, and NGR-TNF, that is, drugs belonging to three different classes of immunomodulatory agents, that are also capable to affect tumor blood vessels with different mechanisms, and discusses the potential role of such agents in NSCLC treatment strategy.
format Text
id pubmed-2896845
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-28968452010-07-07 Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF Corti, Angelo Giovannini, Monica Belli, Carmen Villa, Eugenio J Oncol Case Report Standard treatments for nonsmall cell lung cancer (NSCLC), such as surgery, chemotherapy, and radiotherapy, often lead to disappointing results. Unfortunately, also the various immunotherapeutic approaches so far tested have not produced satisfactory results to be widely applied in the clinical practice. However, the recent development of new immunomodulatory agents may open promising therapeutic options. This paper focuses on PF3512676, lenalidomide, and NGR-TNF, that is, drugs belonging to three different classes of immunomodulatory agents, that are also capable to affect tumor blood vessels with different mechanisms, and discusses the potential role of such agents in NSCLC treatment strategy. Hindawi Publishing Corporation 2010 2010-06-03 /pmc/articles/PMC2896845/ /pubmed/20613952 http://dx.doi.org/10.1155/2010/732680 Text en Copyright © 2010 Angelo Corti et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Corti, Angelo
Giovannini, Monica
Belli, Carmen
Villa, Eugenio
Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF
title Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF
title_full Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF
title_fullStr Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF
title_full_unstemmed Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF
title_short Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF
title_sort immunomodulatory agents with antivascular activity in the treatment of non-small cell lung cancer: focus on tlr9 agonists, imids and ngr-tnf
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2896845/
https://www.ncbi.nlm.nih.gov/pubmed/20613952
http://dx.doi.org/10.1155/2010/732680
work_keys_str_mv AT cortiangelo immunomodulatoryagentswithantivascularactivityinthetreatmentofnonsmallcelllungcancerfocusontlr9agonistsimidsandngrtnf
AT giovanninimonica immunomodulatoryagentswithantivascularactivityinthetreatmentofnonsmallcelllungcancerfocusontlr9agonistsimidsandngrtnf
AT bellicarmen immunomodulatoryagentswithantivascularactivityinthetreatmentofnonsmallcelllungcancerfocusontlr9agonistsimidsandngrtnf
AT villaeugenio immunomodulatoryagentswithantivascularactivityinthetreatmentofnonsmallcelllungcancerfocusontlr9agonistsimidsandngrtnf

Ejemplares similares